{
    "clinical_study": {
        "@rank": "46974", 
        "arm_group": {
            "arm_group_label": "Blinatumomab", 
            "arm_group_type": "Experimental", 
            "description": "All subjects will receive open label Blinatumomab"
        }, 
        "brief_summary": {
            "textblock": "This study seeks adult subjects with R/R Ph+ B-precursor ALL. This is a single-arm Simon II\n      stage design, multicenter study consisting of a screening period, an induction treatment\n      period (2 cycles of blinatumomab), a consolidation treatment period (up to 3 additional\n      cycles of blinatumomab for applicable subjects), and a safety follow-up visit 30 days after\n      treatment. Following the safety follow-up visit, subjects will be followed for response\n      duration and survival every 3 months for 18 months or death, whichever occurs first."
        }, 
        "brief_title": "Phase 2 Trial of Blinatumomab in Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients with Ph+ B-precursor ALL, with any of the following:\n\n        \u2022 Relapsed or refractory to at least one second generation TKI (dasatinib, nilotinib,\n        bosutinib, ponatinib) OR intolerant to second generation TKI and intolerant or refractory\n        to imatinib mesylate\n\n          -  Greater than 5% blasts in bone marrow\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2\n\n          -  Age \u2265 18 years of age, at the time of informed consent.\n\n          -  Subject has provided informed consent or subject's legally acceptable representative\n             has provided informed consent when the subject has any kind of condition that, in the\n             opinion of the Investigator, may compromise the ability of the subject to give\n             written informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02000427", 
            "org_study_id": "20120216"
        }, 
        "intervention": {
            "arm_group_label": "Blinatumomab", 
            "description": "Blinatumomab is administered as a continuous intravenous infusion (CIVI). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval. In the first cycle, the initial dose will be 9 \u03bcg/day for the first 7 days of treatment, a dose that then will be escalated (dose step) to 28 \u03bcg/day starting at day 8 (week 2) through day 29 (week 4).\nFor all subsequent cycles (beginning with the second induction cycle and continuing through consolidation for applicable subjects), 28 \u03bcg/day will be the dose for all 4 weeks of continuous treatment.", 
            "intervention_name": "Blinatumomab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Bispecific"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Relapsed; Refractory;  Philadelphia Positive;  B-precursor;  Acute Lymphoblastic Leukemia; ALL; Blinatumomab; Leukemia;", 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes Cedex 1", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris Cedex 10", 
                        "country": "France", 
                        "zip": "75475"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse cedex 9", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "12200"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "zip": "45122"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt am Main", 
                        "country": "Germany", 
                        "zip": "60590"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "W\u00fcrzburg", 
                        "country": "Germany", 
                        "zip": "97080"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergamo", 
                        "country": "Italy", 
                        "zip": "24127"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "zip": "40138"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "zip": "00161"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Venezia", 
                        "country": "Italy", 
                        "zip": "30174"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Verona", 
                        "country": "Italy", 
                        "zip": "37134"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW3 2PF"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France", 
                "Germany", 
                "Italy", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)", 
        "other_outcome": [
            {
                "measure": "Duration of MRD Remission with blinatumomab treatment", 
                "safety_issue": "No", 
                "time_frame": "Approximately 30 weeks"
            }, 
            {
                "measure": "Efficacy of blinatumomab against specific bcr-abl mutations", 
                "safety_issue": "No", 
                "time_frame": "Approximately 30 weeks"
            }
        ], 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration", 
                "Germany: Paul Ehrlich Institut (PEI)", 
                "France: Agence nationale de s\u00e9curit\u00e9 du medicament et des produits de sant\u00e9 (ANSM)", 
                "Italy: Agenzia Italiana del Farmaco (AIFA)", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with CR/CRh* within 2 cycles of treatment with blinatumomab", 
            "safety_issue": "No", 
            "time_frame": "Approximately 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02000427"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of Participants with MRD remission within 2 cycles of treatment with blinatumomab", 
                "safety_issue": "No", 
                "time_frame": "Approximately 12 weeks"
            }, 
            {
                "measure": "Duration of CR or CRh*", 
                "safety_issue": "No", 
                "time_frame": "Approximately 3 - 4 years"
            }, 
            {
                "measure": "Number of Participants with CR within 2 cycles of treatment with blinatumomab", 
                "safety_issue": "No", 
                "time_frame": "Approximately 12 weeks"
            }, 
            {
                "measure": "Number of Participants with CRh* rate within 2 cycles of treatment with blinatumomab", 
                "safety_issue": "No", 
                "time_frame": "Approximately 12 weeks"
            }, 
            {
                "measure": "Number of Participants with CR+CRh*+ Complete Response incomplete (CRi) rate within 2 cycles of treatment with blinatumomab", 
                "safety_issue": "No", 
                "time_frame": "Approximately 12 weeks"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Approximately 3 - 4 years"
            }, 
            {
                "measure": "Number of Participants undergoing Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) and 100-day mortality after alloHSCT", 
                "safety_issue": "No", 
                "time_frame": "100 days"
            }, 
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability and number of participants withIncidence of adverse events and antibody formation", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 2 - 3 years"
            }, 
            {
                "measure": "Serum concentration of blinatumomab", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 - 3 years"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}